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MEETING REPORT Open Access
Meeting report of the 2017 KidGen Renal
Genetics Symposium
Kushani Jayasinghe1,2*†, Cathy Quinlan2,3,4†, Zornitza Stark2,3,5, Chirag Patel2,6, Matthew G. Sampson7,
Moin Saleem8, Andrew J. Mallett2,9,10 and on behalf of the KidGen Collaborative
Abstract
The 2017 KidGen Renal Genetics Symposium was held at the Royal Children’s Hospital and Murdoch Children’s
Research Institute, Melbourne, from 6 to 8 December 2017. This meeting addressed clinical, diagnostic, and research
aspects of inherited kidney disease. More than 100 clinicians, researchers, and patient representatives attended the
conference. The overall goal was to improve the understanding and direction of genomics in renal medicine in Australia
and discuss barriers to the use of genomic testing within this area. It also aimed to strengthen collaborations between
local, state, and global research and diagnostic and clinical groups.
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Introduction and background to the meeting
There has been a rapid change and progress in the field of
inherited kidney disease and nephrogenetics in recent years,
and this has across clinical, diagnostic, and research
domains. Within an Australian and Australasian perspec-
tive, there have been not only challenges but also opportun-
ities related to this translational process. The obstacles of
geography and distance are countered by nationally and
regionally coordinated genomic efforts such as Australian
Genomics, Melbourne Genomics, and the Queensland
Genomic Health Alliance. The annual KidGen Renal
Genetics Symposium provides an opportunity to bring
together a diversity of clinicians, researchers, and patient
representatives from around Australia, Australasia, and the
global community. This enables a unique opportunity to
better understand the renal genetics implementation
landscape while updating on the latest progress within a
strong nexus of collaboration focused on this particular
emerging subspecialty field.
The renal genetics multidisciplinary workshop
This interactive half-day clinical workshop, convened by
Dr. Chirag Patel from Genetic Health Queensland, was
designed primarily for nephrologists, geneticists, and
genetic counselors new to the clinical practice of renal
genetics. Thirty participants attended the workshop, with
small groups of six including a facilitator. Participants in
each group comprised of a mixture of professionals, which
included adult and pediatric nephrologists, genetic
counselors, and clinical geneticists, reflecting the typical
composition of a multidisciplinary clinic or meeting.
Case-based scenarios were discussed including pertinent
issues in each case, differential diagnosis, information
required, counseling and ethical issues, and genetic testing
indications and results. All participants also took part in a
survey to evaluate their initial understanding of genomics
and confidence in renal genetics cases, and these survey
findings will be analyzed as part of an implementation
science analysis of renal genetics in Australia.
Providing a map of services available to date
Dr. Andrew Mallett, the National Director of the KidGen
Collaborative and the Australian Genomics Health Alliance
(AGHA) Renal Genetics Flagship, presented on the renal
genetics services and research opportunities in Australia.
The KidGen Collaborative continues to grow and evolve. In
the last year, services have commenced in South Australia
and Western Australia (Fig 1). Multidisciplinary renal
genetics clinics will soon be underway in Darwin and
Tasmania, with the aim to provide access to 90% of the
Australian population over the next 12 months. Dr. Mallett
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also described the challenges of recruiting to the Australian
Genomics renal flagship. Potential participant recruitment
rates have not been as high as projected, and research look-
ing into reasons for this is being conducted via an imple-
mentation science project. Another exciting new venture is
the Australian Genomics “wHole genome Investigation to
iDentify unDEtected Nephropathies (HIDDEN) Flagship”
which has recently secured funding to identify undetected
genetic nephropathies using whole genome sequencing.
Currently, 5% of patients with end-stage kidney disease
(ESKD) have an unknown cause of their renal failure. With
the cost of genome sequencing decreasing, there is an
opportunity to remediate this. The immediate aim is to
evaluate 200 participants with unexplained ESKD over
the next 24 months. He also highlighted that significant
prospective studies evaluating the cost-effectiveness of
genomic testing are occurring in Australian cohorts,
which will be crucial in securing sustainable funding
for genomic testing in routine healthcare.
Rare inherited kidney disease registries
This session focused on the opportunities and challenges
of developing rare disease registries. Professor Moin
Saleem, Head of Bristol Renal, a world renowned
glomerular disease research group, presented on the
United Kingdom (UK) approach to rare inherited kidney
disease. Rare inherited kidney disease refers to diseases
that have a prevalence of 1 in 2000 [1]. Up to 10% of the
population will have a rare disease, and 80% of rare
diseases will have a genetic basis. The UK renal community
has developed perhaps the world leading system for
ongoing collation of cohorts of patients with renal rare
disease, called renal RaDaR (www.rarerenal.org). This is a
web-based and nationally inclusive program, which allows
information to build in a bottom-up fashion, driven by
interested and enthusiastic stakeholders, professionals, and
patients. This registry was developed utilizing the informa-
tion technology (IT) infrastructure of the UK renal registry.
The original target of the registry was to recruit 500
patients, whereas currently, there are over 15,000 patients
comprising 25 patient groups and 85 renal units.
Professor Saleem described the importance of
understanding rare disease using modern biological
advances. In order to stratify and treat patients
appropriately, we must move from descriptive classifi-
cations to molecular levels of understanding. To do
this, it is crucial to recruit as many patients as
possible in order to facilitate studies with sufficient
analytical power. The RaDaR registry has also
provided the opportunity to create rare disease groups
and facilitated the development of evidence-based
care pathways and further empower patients. There
are tremendous opportunities that arise from such
registries, and other countries can benefit from the
lessons learned from the UK renal registry.
Fig. 1 Location of KidGen-affiliated Renal Genetics Clinics as of 7 December 2017
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Genomic profiling and molecular insights in
nephrotic syndrome
Keynote speakers presented on the benefits of deep clinical
and genomic profiling in nephrotic syndrome. Professor
Saleem discussed the importance of discovering robust
biological biomarkers that identify patients with circulating
factor disease. For example, there is strong evidence for a
role of a circulating factor in the pathogenesis of idiopathic
nephrotic syndrome (iNS) [2, 3]. Previous work has
suggested a role for protease-activated receptor (PAR-1)
[4]. His group used a model whereby a transgenic mouse
was developed that expressed a podocyte-specific constitu-
tively active form of PAR-1 in order to replicate overexpos-
ure to a circulating protease. The developmental PAR-1
active mice were born normal and died consistently
between the ages of 39 and 45 days. Proteinuria developed
from 14 days and markedly increased over time. Electron
microscopy (EM) analysis showed a significantly thickened
glomerular basement membrane (GBM) and foot process
effacement. This demonstrated a clear role for the PAR-1
receptor in proteinuria and strengthened the hypothesis
that circulating factor(s) may act via this receptor.
Additionally, this is a novel model for circulating factor
nephrotic syndrome (NS) to test therapies in vivo. Professor
Saleem presented this work at the recent American Society
of Nephrology Kidney Week in November 2017.
Dr. Matthew Sampson, a pediatric nephrologist and re-
searcher at the University of Michigan, spoke on the use
of population genetics to interrogate monogenic nephrotic
syndrome diagnosis. His laboratory combines innovative
genomic technologies, statistical genetics, computational
genetics, and bioinformatics to elucidate the role of
genomic variation in renal disease. Genomic discovery in
nephrotic syndrome has allowed insight into biology of
disease, clinical correlates such as prognosis and
treatments, and prevalence estimates of disease.
Monogenic nephrotic syndrome is a serious form of NS,
and these patients often have a continued decline in kidney
function that is resistant to immunosuppressive therapy.
[5–9]. There are over 60 causative genetic mutations of ster-
oid resistant nephrotic syndrome (SRNS) [10]. Numerous
publications have reported robust genotype-phenotype cor-
relations in monogenic NS and their substantial prevalence.
Previously, diagnostic genetic screening involved sequencing
one or two genes most likely to harbor causal variants in
patients with a high pretest probability of having a genetic
form of nephrotic syndrome. Once found, other evidence
was collected to support causality. Nowadays, genomic
technologies are rapidly evolving, enabling sequencing to
become much more readily available. Hence, there is a
widespread enthusiasm from all stakeholders to expand
sequencing efforts in affected patients to make a diagnosis
of “monogenic NS.” However, there is a need to assess the
generalizability of prevalence estimates and clinical
correlates previously reported from selected cohorts now
that more patients and more genes can be studied. One
aspect of this is the recognition from large-scale sequencing
projects in reference populations that the prevalence of pu-
tatively fully penetrant mutations in the general population
can be orders of magnitude higher than the reported disease
prevalence.
The NEPTUNE study [11] is a North American cohort
of NS patients that provided a laboratory to gain insights
on the challenges of making a monogenic diagnosis in
previously understudied populations. Patients with NS
were enrolled at the time of the first biopsy and inde-
pendent of age, ancestry, and response to immunosup-
pression. They were then followed longitudinally. In a
paper by Sampson et al. [12], 312 patients underwent
targeted sequencing of 21 genes implicated in SRNS.
These were compared to the 1000 Genomes Project
(1000G) reference population. A typical pathogenicity
filter identified causal variants for NS in 4.2% of patients
and 5.8% of subjects from the 1000G. The group then
devised a more stringent pathogenicity filtering strategy,
implicating monogenic NS in 2.9% of NEPTUNE
patients and reducing background prevalence of causal
variants to 1.5% in the 1000G. Interestingly, patients
with putative monogenic NS in NEPTUNE achieved
complete remission of proteinuria at similar rates to
those without a monogenic diagnosis.
The 1.5% background prevalence suggests that some
variants, even if found in patients, might be either incor-
rectly implicated as pathogenic. In addition, there may
be a greater degree of incomplete penetrance of these
variants than previously appreciated. Therefore, in an
unselected cohort, it may be accurate to consider a
monogenic diagnosis from a probabilistic and not a
deterministic perspective.
Functional genomics
Professor Melissa Little, the theme Director of Cell
Biology at Murdoch Children’s Research Institute (MCRI)
in Melbourne and program leader of Stem Cells Australia,
discussed the clinical and research applications for in-
duced pluripotent stem cells and their application in kid-
ney disease. Advances in next-generation sequencing have
improved diagnosis rates for families with inherited kidney
disease; however, a causative gene is identified in only 40%
of cases [13]. While novel potential causative gene associa-
tions are being identified, these still require functional
validation. The use of induced pluripotent stem cells
(iPSC) is one approach that has the potential to determine
the functional significance of previously un-described gene
variants. Professor Little and her team developed a proto-
col for the successful differentiation of human pluripotent
stem cells to a kidney organoid [14, 15]. This results in the
formation of a complex organoid containing all cellular
Jayasinghe et al. Human Genomics  (2018) 12:5 Page 3 of 6
components anticipated for a first trimester human
kidney. Professor Little also presented data illustrating
how we can replicate the disease phenotype of an
inherited kidney disease. By modeling heritable kidney
disease and screening of toxicity and efficacy, we are
now able to move towards applying stem cells to cellular
therapy. Renal replacement therapy through iPSC-derived
cells is still some time away, mainly due to barriers of scale
and vascular supply.
Challenges in genomic medicine
This session focused on current challenges in implementing
genomic medicine into clinical practice as well as the in-
novative opportunities and solutions achieved to date. Elly
Lynch, a clinical project manager at Melbourne Genomics
Health Alliance (MGHA), highlighted the potential health
implications from incidental or secondary results that arise
from genomic sequencing. This refers to variants found in-
cidentally through genomic sequencing that are not related
to the aim of the test but may still have potential health
implications and clinical significance [16].
In 2013, the American College of Medical Genetics
and Genomics (ACMG) published a policy statement
that emphasized the importance of reporting of inciden-
tal results [17]. In 2014, the ACMG revised these recom-
mendations to include options for individuals to opt out
of being informed of incidental findings. The ACMG
Board of Directors created the ACMG Secondary Findings
Maintenance Working Group (SFWG) in 2014 to define
and implement a process for updating a minimum list of
secondary findings that would be updated and refined
regularly. The 2016 update statement concluded that
“Informed consent is necessary, and reporting of second-
ary findings should be optional” [18]. However, surpris-
ingly, the research into this area has reflected that often,
patients want to be informed of secondary findings, even
when limited treatment options are available [19].
Professor Kathryn North, co-chair of the Global
Alliance for Genomics and Health (GA4GH) and lead of
the Australian Genomics Health Alliance, highlighted
the challenges of the implementation of genetic services
in Australia. She provided insight into the complex and
fragmented structure of the Australian healthcare sys-
tem. Federal funding for genetic services is currently
limited to about 30 tests and genomic testing being sup-
ported by clinical services at a state level. This
highlighted the importance of linking and collaborating
state-based expertise and investment with the formation
of national flagships in order to facilitate research, map
disparity, and inequity and allow coordinated
collaboration between states.
She also highlighted the importance of global collabor-
ation. In October 2017, Australian Genomics was nomi-
nated a Driver Project of the GA4GH, an international,
nonprofit alliance of over 470 organizations across over
45 countries. Australian Genomics will serve alongside
Genomics England and the All of Us research program
to enable GA4GH to deliver its new 5-year strategic plan
to enable the responsible sharing of clinical-grade
genomic data by 2022.
The benefits of rapid genomic testing in acute
pediatrics
A/Prof Zornitza Stark, clinical geneticist at the Victorian
Clinical Genetics Service (VCGS) and clinical research
fellow with Australian Genomics, demonstrated the
significant clinical and cost benefits from rapid whole
exome sequencing (rWES) in a prospective cohort of 40
acutely unwell pediatric patients recruited through the
Melbourne Genomics Health Alliance in 2016–2017. In
the course of the project, the overall time-to-result
decreased tenfold from 109 to 9 days (median 16 days).
This required whole-of-system change, with over 20
changes implemented to clinical and laboratory processes
to accelerate result delivery. Of the 40 patients who under-
went rWES, 52% received a genetic diagnosis, and 57% of
those diagnosed had a change in management as a result,
including the provision of life-saving treatment, avoidance
of invasive biopsies, and redirection towards palliative
care. Rapid exome sequencing was also very cost-effective,
with cost savings from improved management conservatively
estimated to be around AU$550,000 (Stark Z, Lunke S et al:
Meeting the challenges of implementing rapid genomic test-
ing in acute pediatric care, submitted).
Genomics in specific ethnic groups
This session focused on genetic variation in patients with
chronic kidney disease within Indigenous populations, as
well as the lessons learned and challenges of research in
various ethnic groups. Matthew Sampson presented on the
racial disparity of ESKD in the American population.
African-Americans make up only 13% of the US population
yet make up 32% of all Americans with ESKD [20].
African-Americans who carry two variant alleles within
apolipoprotein L1 (APOL1) are classified as having a high-
risk (HR) genotype [21]. People with HR genotype have an
increased risk of focal segmental glomerulosclerosis and
chronic kidney disease compared with those with a low-
risk (LR) genotype. Children from two cohorts with HR
genotype were characterized (Chronic Kidney Disease in
Children (CKiD) and NEPTUNE), which found that
children with a HR genotype had a more aggressive form of
glomerular disease [22].
William Wong, a pediatric nephrologist at Starship
Children’s Hospital, Auckland, discussed the congenital
nephrotic syndrome in Maori children. Maori children
tend to have a milder course compared to infants with
Caucasian background. Nephrin mutation analysis in 19
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surviving CNS patients revealed a variety of different
mutations in NPS1, with Caucasian infants demonstrat-
ing completely different mutations to Maori infants [23].
Madhivanan Sundaram, a nephrologist at Royal Darwin
hospital, presented on the practical challenges in the diagno-
sis and management of inherited kidney disorders in remote
Indigenous patients. Due to language barriers, cultural bar-
riers, and scarcity of resources in remote communities, there
are many challenges nephrologists face in this population
group. Some of these include difficulties in pedigree analysis,
obtaining informed consent, and reluctance to participate in
research. Some solutions to overcoming these obstacles
include involving genetic counselors from indigenous
groups, increased use of interpreters, and close links with
local community groups and clinics.
Panel discussion: “You can’t always get what you
want – whole genome sequencing, whole exome
sequencing and renal gene panels”
Panelists:
A/Prof Julie McGaughran: Director of Genetic Health
Queensland, Royal Brisbane and Women’s Hospital,
Brisbane
Dr. Cas Simons: Adjunct Senior Fellow, Institute for
Molecular Bioscience, University of Queensland, Brisbane
Dr. Amali Mallawaarachchi: Adult Nephrologist and
Clinical Genetics Fellow, Liverpool Hospital, Sydney
A/Prof Bruce Bennetts: Associate Professor and Head
of Department of Genetic Medicine, Children’s Hospital
at Westmead, Sydney
Dr. Sebastian Luke: Head of the Translational Genomics
Unit, Victorian Clinical Genetics Services and Murdoch
Children’s Research Institute, Melbourne
A/Prof Zornitza Stark: Clinical Geneticist, Victorian
Clinical Genetics Services and Australian Genomics Health
Alliance, Melbourne
The panel discussion allowed a passionate group of
physicians, geneticists, scientists, and counselors the
opportunity to ask thought-provoking questions and
participate in open-minded discussions on the major
topics surrounding genomics in renal medicine. Urgent
unmet needs and challenges in the future were
addressed. Issues raised included the “best test” in the
eyes of laboratory and research scientists versus clinical
geneticists and renal physicians and the balance between
cost of sequencing and selecting the optimal test for the
patient. Overall, the consensus among panel members
was that the current cost of whole genome sequencing is
prohibitive to its clinical use and hence does not justify
the cost of doing this over whole exome sequencing or
targeted panel. Furthermore, we do not know enough
about the whole genome yet to be able to fully interpret
the sequencing results. It is still unclear who should be
the gatekeepers to genetic testing in the future. Should
any doctor be able to order genetic tests? Who is re-
sponsible for counseling patients? Currently, this differs
from state to state, but in general, patients seen in renal
genetics clinics are discussed at multidisciplinary meet-
ings to ensure appropriate test ordering. The general con-
sensus was that genetic testing should primarily be
ordered if it would change patient management.
Conclusions and outcomes
The KidGen Renal Genetics Symposium is currently one
of the few dedicated renal genetics meetings to be held
internationally on an annual basis. In 2017, the 5th
annual meeting brought together scientific researchers,
clinical researchers, adult and pediatric nephrologists,
patient representatives, clinical geneticists, and genetic
counselors. This model exemplifies how research collab-
oration should be facilitated, as it brings together the
key members and stakeholders that can advance the field
of renal genomics. This is of utmost importance to benefit
patients and families with inherited kidney disease. The
symposium provided not only the increased awareness of
the challenges of genomics we face now and into the
future but also the promise of insights and advances that
are continuously being gained.
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